Market Overview

The Global Gene Therapy Market was valued at USD 5,661.3 million in 2023 and is expected to reach USD 41,049.3 million by 2031 while growing at a CAGR of 28.1% during the forecast period (2024-2031). 

 *Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Market Dynamics

This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global gene therapy market growth. Gene therapy is a medical technique aiming to introduce, alter, or replace genetic material in a person's cells to treat or prevent diseases. Its objective is to correct or modify the function of genes that are absent or malfunctioning, achieved through introducing a functional gene copy, repairing a mutated gene, or regulating gene expression.

Advancements in Genetic and Molecular Biology, coupled with a rising incidence of genetic disorders, are poised to drive the gene therapy market. However, challenges such as high development costs, safety concerns, and adverse events may impede market expansion.

Furthermore, the global gene therapy industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.

Segmentation – By Indication Analysis

The Global Gene Therapy Market is segmented among Cancer, Metabolic Disorders, Eye Disorders, Spinal Muscular Atrophy, and Other Indications, based on Indication. In 2023, Cancer accounted for the majority of the market share*. 

 *Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Segmentation – By Technology Analysis

The Global Gene Therapy Market is segmented among Adeno Virus Vector, Adeno-associated Virus Vector, Lentiviral Vector, Retroviral Vector, Herpes Virus Vector, and Other Technologies, based on Technology. In 2023, Adeno Virus Vector accounted for the majority of the market share*. 

 *Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Global Gene Therapy Market: Regional Analysis

Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Europe is expected to grow with the highest CAGR during the forecast period (2024 – 2031). 

 *Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Competitive Landscape

Some of the key players operating in the market are Amgen Inc., Biogen Inc., Bluebird Bio Inc., Gilead Sciences Inc. (Kite Pharma), Novartis AG, F. Hoffmann-La Roche Ltd (Spark Therapeutics), UniQure NV, Abeona Therapeutics Inc., Generation Bio, and Poseida Therapeutics.

Table of Contents:

1. Research Methodology and Market Scope

• Research Methodology

• Market Scope

2. Executive Summary

3. Global Gene Therapy Market Dynamics

• Drivers

• Restraints

• Opportunity

4. Global Gene Therapy Industry Analysis

• PEST Analysis

• Porter's Five Force Analysis

• Recent Deals Analysis

5. Global Gene Therapy Market Segmentation, By Indication

• Global Gene Therapy Market Share Analysis, By Indication

• Global Gene Therapy Market Growth Analysis, By Indication

• Global Gene Therapy Market Trends, By Indication

o Cancer

o Metabolic Disorders

o Eye Disorders

o Spinal Muscular Atrophy

o Other Indications

6. Global Gene Therapy Market Segmentation, By Technology

• Global Gene Therapy Market Share Analysis, By Technology

• Global Gene Therapy Market Growth Analysis, By Technology

• Global Gene Therapy Market Trends, By Technology

o Adeno Virus Vector

o Adeno-associated Virus Vector

o Lentiviral Vector

o Retroviral Vector

o Herpes Virus Vector

o Other Technologies

7. Global Gene Therapy Market Segmentation, By Region

• Global Gene Therapy Market Share Analysis, By Region

• Global Gene Therapy Market Growth Analysis, By Region

• Global Gene Therapy Market Trends, By Region

o North America

o Europe

o Asia Pacific

o Latin America

o Middle East

o Africa

8. Competitive Landscape

• Amgen Inc.*

o Company Overview

o Financial Performance

o Key Development/Strategies

o SWOT Analysis

• Biogen Inc.

• Bluebird Bio Inc.

• Gilead Sciences Inc. (Kite Pharma)

• Novartis AG

• F. Hoffmann-La Roche Ltd (Spark Therapeutics)

• UniQure NV

• Abeona Therapeutics Inc.

• Generation Bio

• Poseida Therapeutics

*Similar analysis will be provided for each company listed above.